Holen Sie sich die Stockscreener-App
16.23
6.46%
-1.12
Handel nachbörslich:
16.30
0.07
+0.43%
Schlusskurs vom Vortag:
$17.35
Offen:
$17.35
24-Stunden-Volumen:
1.28M
Relative Volume:
2.52
Marktkapitalisierung:
$1.60B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-0.12%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.18
$17.54
1-Wochen-Bereich:
$16.18
$17.80
52-Wochen-Spanne:
$14.62
$18.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Firmenname
Definium Therapeutics Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
16.23 | 1.71B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
Is Adsett’s Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
Pharma Co. Stole Secrets For LSD Medical Trials, Suit Says - Law360
Definium Therapeutics Announces New Employee Inducement GrantsFebruary 3, 2026 - BioSpace
Definium Therapeutics stock hits 52-week high at 18.19 USD By Investing.com - Investing.com Nigeria
LSD therapy biotech Definium sued for alleged trade secret theft | Business Information & News | FE - Westlaw Today
LSD therapy biotech Definium sued for alleged trade secret theft - Reuters
Company Researching LSD Applications Faces Trade Secrets Litigation in Delaware Federal Court - Law.com
Definium Therapeutics (NASDAQ:DFTX) Hits New 52-Week HighShould You Buy? - MarketBeat
Definium Therapeutics stock hits 52-week high at 18.19 USD - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Definium stock By Investing.com - Investing.com UK
Cantor Fitzgerald reiterates Overweight rating on Definium stock - Investing.com
Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Jefferies Financial Group - Defense World
Did Adding Biopharma Veteran Roger Adsett to the Board Just Shift Definium Therapeutics' (DFTX) Investment Narrative? - Yahoo Finance
Definium Therapeutics (NASDAQ:DFTX) Upgraded to Strong-Buy at Jefferies Financial Group - MarketBeat
Roger Adsett Joins Definium As Commercial Focus Meets Trial Milestones - Yahoo Finance
Definium Therapeutics Adds Commercial Leader As Phase 3 Milestones Approach - Sahm
Commit To Buy Definium Therapeutics At $10, Earn 21.9% Annualized Using Options - Nasdaq
Jefferies Initiates Coverage on Definium Therapeutics With Buy Rating, $30 Price Target - marketscreener.com
Jefferies initiates coverage on Definium Therapeutics stock with Buy rating - Investing.com India
Definium Therapeutics appoints Roger Adsett to board of directors By Investing.com - Investing.com Nigeria
Jefferies initiates coverage on Definium Therapeutics stock with Buy rating By Investing.com - Investing.com UK
Critical Contrast: Definium Therapeutics (NASDAQ:DFTX) vs. Tetra Bio-Pharma (OTCMKTS:TBPMF) - Defense World
Definium Therapeutics (DFTX) Expands Board with New Appointment - GuruFocus
Definium Therapeutics Appoints Roger Adsett To Board - citybiz
Definium Therapeutics Appoints Roger Adsett to Board of Directors, Effective from January 29, 2025 - marketscreener.com
Definium Therapeutics Expands Board, Appoints New Director - TipRanks
Definium Therapeutics appoints Roger Adsett to board of directors - Investing.com
Definium Therapeutics Appoints Roger Adsett to Board of Directors - Yahoo Finance
Will Definium's ‘Rerouting Minds’ LSD Education Push Recast DFTX’s Science-First Psychedelic Narrative? - simplywall.st
Certain Pre-funded warrants of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2026. - marketscreener.com
Breakthrough or Bubble? The High-Stakes 2026 Readouts for Psychedelic Giants - geneonline.com
DFTX Stock Price and Chart — NASDAQ:DFTX - TradingView
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - Defense World
A Look At Definium Therapeutics (DFTX) Valuation After Rerouting Minds Campaign Highlights Psychedelic LSD Programs - simplywall.st
Definium Therapeutics (FRA:MMQ0) Momentum Rank : 2 (As of Jan. 24, 2026) - GuruFocus
DFTX: RBC Capital Raises Price Target for Definium Therapeutics - GuruFocus
Definium Therapeutics stock price target raised to $36 from $20 at RBC Capital - Investing.com India
RBC Raises Price Target on Definium Therapeutics to $36 From $20, Keeps Outperform, Speculative Risk - marketscreener.com
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's What Happened - MarketBeat
Deinium Therapeutics (DFTX) Is Up 11.5% After Psychedelic Rebrand And DT120 Roadmap Reveal Has The Bull Case Changed? - Sahm
Definium launches educational campaign on LSD for mental health By Investing.com - Investing.com South Africa
Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry - TipRanks
Finanzdaten der Definium Therapeutics Inc-Aktie (DFTX)
Es liegen keine Finanzdaten für Definium Therapeutics Inc (DFTX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Definium Therapeutics Inc-Aktie (DFTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer |
Dec 26 '25 |
Sale |
13.15 |
25,791 |
339,072 |
778,477 |
| Sullivan Mark | Chief Legal Officer |
Dec 26 '25 |
Sale |
13.15 |
11,276 |
148,244 |
282,576 |
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):